Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Cyteir Therapeutics, Inc. (CYT)
|
Add to portfolio |
|
|
|
| Price: |
$9.97
| | Metrics |
| OS: |
36.0
|
M
| |
-32
|
% ROE
|
| Market cap: |
$359
|
M
| |
-5456
|
% ROIC
|
|
Net cash:
|
$134
|
M
| |
$3.71
|
per share
|
|
EV:
|
$225
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
($46.7)
|
M
| |
|
|
| EPS |
($1.15)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-05-22 | Dec-31-21 | Dec-05-21 | Dec-31-20 | Dec-31-19 |
| Revenues | 34.6 | 0.0 | 31.0 | 0.0 | 12.8 |
| Revenue growth | 11.8% | | | -100.0% | |
| Cost of goods sold | 48.2 | 0.0 | 42.3 | 0.0 | 25.5 |
| Gross profit | -13.5 | 0.0 | -11.3 | 0.0 | -12.8 |
| Gross margin | -39.1% | | -36.5% | | -99.9% |
| Selling, general and administrative | | 42.3 | | 20.9 | |
| General and administrative | 13.5 | | 11.3 | | 3.3 |
| EBIT | -48.2 | -42.0 | -42.3 | -20.7 | -16.1 |
| EBIT margin | -139.1% | | -136.5% | | -126.1% |
| Pre-tax income | -46.1 | -42.1 | -42.1 | -20.8 | -15.0 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | | 0.0% |
| Net income | -46.1 | -42.1 | -42.1 | -20.8 | -15.0 |
| Net margin | -133.0% | | -136.1% | | -117.8% |
| |
| Diluted EPS | ($1.31) | ($2.16) | ($2.16) | ($13.60) | ($0.01) |
| Shares outstanding (diluted) | 35.3 | 19.5 | 19.5 | 1.5 | 1,290.2 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|